Buvat J, Buvat-Herbaut M, Lemaire A, Marcolin G
Association pour l'Etude de la Pathologie de l'Appareil Reproducteur et de la Psychosomatique (EPARP), Lille.
Contracept Fertil Sex. 1993 Feb;21(2):173-6.
The alpha-blocking agent Moxisylyte was tested in auto-intracavernous injections (auto-ICI) in 72 impotent patients. The side-effects were compared to those observed in a group of 34 impotent patients treated with auto-ICI of Papaverine during the same period of time. The Moxisylyte auto-ICI improved 83% of the patients including 68% reporting a complete and durable success. Moxisylyte proved to be safer due to a reduced rate of prolonged erections (1.3% of the patients versus 8.8% with Papaverine) and corporeal fibrosis (1.3% versus 32% with Papaverine). Though less potent than Papaverine, and often seeming insufficient when tested in the office, this type of alpha-blocking agent could be tried in a first time in most candidates to auto-ICI before resorting to Papaverine or Prostaglandin E1 if it fails.
对72例阳痿患者进行了α-阻滞剂莫西赛利的海绵体内自我注射（自我海绵体内注射，auto-ICI）试验。将其副作用与同期34例接受罂粟碱自我海绵体内注射治疗的阳痿患者所观察到的副作用进行了比较。莫西赛利自我海绵体内注射使83%的患者病情改善，其中68%报告完全且持久有效。事实证明，莫西赛利更安全，因为阴茎异常勃起的发生率降低（患者中占1.3%，而罂粟碱为8.8%），以及海绵体纤维化发生率降低（分别为1.3%和32%）。尽管莫西赛利的效力不如罂粟碱，且在门诊测试时往往似乎效果不佳，但在大多数适合自我海绵体内注射的患者中，可先尝试使用这种α-阻滞剂，若失败再使用罂粟碱或前列腺素E1。
